Shanghai Key Laboratory of Tuberculosis, Clinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
BMC Biol. 2019 Jan 25;17(1):7. doi: 10.1186/s12915-019-0628-6.
The emergence of drug-resistant strains of Mycobacterium tuberculosis (Mtb), especially those that are multidrug resistant poses a serious threat to global tuberculosis control. However, the mechanism underlying the occurrence of drug resistance against more than one drug is poorly understood. Given that the Beijing/W strains are associated with outbreaks and multidrug resistance, they may harbor a genetic advantage and provide useful insight into the disease. One marker found in all Beijing/W Mtb strains is a deletion of RD105 region that results in a gene fusion, Rv0071/74, with a variable number (3-9 m) of VDP (V: Val, D: Asp; P: Pro) repeats (coded by gtggacccg repeat sequences) at the N-terminal. Here, we report that this variable number of VDP repeats in Rv0071/74 regulates the development of multidrug resistance.
We collected and analyzed 1255 Beijing/W clinical strains. The results showed that the number of VDP repeats in Rv0071/74 was related to the development of multidrug resistance, and the deletion of Rv0071/74-9 m from Beijing/W clinical strain restored drug susceptibility. Rv0071/74-9 m also increased resistance to multiple drugs when transferred to different mycobacterial strains. Cell-free assays indicate that the domain carrying 4-9 VDP repeats (4-9 m) showed a variable binding affinity with peptidoglycan and Rv0071/74 cleaves peptidoglycan. Furthermore, Rv0071/74-9 m increased cell wall thickness and reduced the intracellular concentration of antibiotics.
These findings not only identify Rv0071/74 with VDP repeats as a newly identified multidrug resistance gene but also provide a new model for the development of multiple drug resistance.
结核分枝杆菌(Mtb)耐药株的出现,尤其是耐多药株,对全球结核病控制构成了严重威胁。然而,对一种以上药物产生耐药性的机制尚不清楚。鉴于北京/W 株与暴发和耐多药有关,它们可能具有遗传优势,并为该疾病提供有用的见解。所有北京/W Mtb 株都存在一个标记,即 RD105 区缺失,导致基因融合 Rv0071/74,其 N 端有可变数量(3-9 个)的 VDP(V:缬氨酸,D:天冬氨酸;P:脯氨酸)重复(由 gtggacccg 重复序列编码)。在这里,我们报告 Rv0071/74 中的可变数量 VDP 重复调节耐多药的发展。
我们收集并分析了 1255 株北京/W 临床株。结果表明,Rv0071/74 中的 VDP 重复数量与耐多药的发展有关,北京/W 临床株中 Rv0071/74-9m 的缺失恢复了药物敏感性。Rv0071/74-9m 也增加了转移到不同分枝杆菌株时对多种药物的耐药性。无细胞测定表明,携带 4-9 个 VDP 重复(4-9m)的结构域与肽聚糖具有可变的结合亲和力,并且 Rv0071/74 切割肽聚糖。此外,Rv0071/74-9m 增加了细胞壁厚度并降低了细胞内抗生素浓度。
这些发现不仅确定了带有 VDP 重复的 Rv0071/74 是一个新发现的耐多药基因,而且为多种耐药性的发展提供了一个新的模型。